Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $84.20.

A number of research analysts recently issued reports on ARWR shares. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. JPMorgan Chase & Co. started coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They issued an “overweight” rating and a $88.00 target price on the stock. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. Chardan Capital boosted their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, B. Riley Financial upped their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd.

Arrowhead Pharmaceuticals Trading Down 1.9%

NASDAQ:ARWR opened at $74.93 on Friday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals has a 1-year low of $12.44 and a 1-year high of $77.90. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of 48.97 and a beta of 1.28. The business’s 50-day moving average price is $63.70 and its two-hundred day moving average price is $59.78.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.Arrowhead Pharmaceuticals’s quarterly revenue was up 10461.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.39) earnings per share. On average, equities analysts expect that Arrowhead Pharmaceuticals will post -3.37 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the sale, the insider owned 226,958 shares of the company’s stock, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. This trade represents a 7.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 33,095 shares of company stock valued at $2,326,228. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. CWM LLC lifted its stake in Arrowhead Pharmaceuticals by 1.4% in the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after buying an additional 168 shares in the last quarter. First Horizon Corp increased its position in shares of Arrowhead Pharmaceuticals by 36.3% during the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 174 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 1.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock worth $737,000 after acquiring an additional 178 shares during the period. HighTower Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock worth $8,845,000 after acquiring an additional 340 shares during the period. Finally, Maryland State Retirement & Pension System lifted its position in Arrowhead Pharmaceuticals by 1.8% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company’s stock valued at $1,344,000 after acquiring an additional 365 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.